EpiBiologics, a biotech leader in tissue-selective extracellular protein degradation, announced the completion of a $107 million Series B financing round co-led by GV (Google Ventures) and Johnson & Johnson Innovation – JJDC.
The round also drew in Novartis Venture Fund (NVF), Aulis Capital, Avego BioScience Capital, and Samsara BioCapital, alongside returning investors Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital.
“We’re delighted to work with this distinguished group of investors as we enter the next stage of EpiBiologics’ growth. This financing allows us to advance our pipeline of novel bispecific antibodies to selectively degrade disease-driving membrane and soluble targets in oncology and immunology,” said Ann Lee-Karlon, Chief Executive Officer of EpiBiologics.
"Our lead program, EPI-326, is moving rapidly to the clinic as a highly differentiated therapeutic to address substantial unmet needs for patients with EGFR-driven cancers.”
EPI-326 is a tissue-selective bispecific antibody designed to degrade all oncogenic forms of EGFR. The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue.
Preclinical studies show strong, durable efficacy, favorable safety, and promising pharmacokinetics, supporting both monotherapy and combination approaches across multiple cancer types.
EpiBiologics plans to launch a first-in-human clinical trial of EPI-326 in early 2026, targeting non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). The company also strengthened its leadership team in 2025 with the appointments of Eric Humke, as Chief Medical Officer and Aaron Mishel as Chief Financial Officer.
“As an early investor, I’ve been impressed by EpiBiologics’ rapid scientific and operational progress as they’ve built the EpiTAC platform and portfolio in oncology, immunology, and beyond,” said David Schenkein, General Partner at GV.
